On the other hand, CD20-targeted B cell depletion has also been reported to spare PCs in patients with autoimmune disease treated with rituximab [48, 49] and in mice [50], and response to rituximab is reduced in patients with RA with higher levels of a plasmablast-specific marker, IgJ [51]. This evidence concerns the gene JCHAIN and autoimmune disease.